Custom Truck One Source Announces Fourth Quarter and Full-Year 2024 Earnings Release and Conference Call
KANSAS CITY, Mo., February 11, 2025--(BUSINESS WIRE)--Custom Truck One Source, Inc. (NYSE: CTOS) today announced it will release financial results for the fourth quarter and full year 2024 after the market close on Tuesday, March 4, 2025.
Management will discuss the results on a conference call at 9:00 a.m. ET on Wednesday, March 5, 2025. An audio-only webcast of the conference call and a presentation of financial information will be available at investors.customtruck.com. To listen by phone, please dial 1-800-715-9871 or 1-646-307-1963 and provide the operator with conference ID 5195913. A replay of the call will be available until 11:59 p.m. ET, Wednesday, March 12, 2025, by dialing 1‑800-770-2030 or 1-609-800-9909 and entering the passcode 5195913 followed by the # key.
ABOUT CUSTOM TRUCK ONE SOURCECustom Truck One Source is one of the largest providers of specialty equipment, parts, tools, accessories and services to the electric utility transmission and distribution, telecommunications and rail markets in North America, with a differentiated "one-stop-shop" business model. The Company offers its specialized equipment to a diverse customer base for the maintenance, repair, upgrade and installation of critical infrastructure assets, including electric lines, telecommunications networks and rail systems. The Company's coast-to-coast rental fleet of more than 10,000 units includes aerial devices, boom trucks, cranes, digger derricks, pressure drills, stringing gear, hi-rail equipment, repair parts, tools and accessories. For more information, please visit customtruck.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250211801777/en/
Contacts
INVESTOR CONTACT Brian Perman, Vice President, Investor Relations816-723-7906investors@customtruck.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Johnson Fistel Continues Investigation on Behalf of SentinelOne, Inc. Shareholders
SAN DIEGO--(BUSINESS WIRE)--Johnson Fistel, PLLP is investigating claims on behalf of SentinelOne, Inc. (NYSE: S) against certain of its officers and directors. If you are a current, long-term shareholder of SentinelOne, continuously holding shares since June 1, 2022, you may have standing to hold the company harmless from the alleged harm caused by the Company's officers and directors by making them personally responsible. You may also be able to assist in reforming the Company's corporate governance to prevent future wrongdoing. You can click or copy and paste the link below in a browser to join this action: Previously, a class action complaint was filed against the company. The class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) SentinelOne lacked effective internal controls over accounting and financial reporting; (ii) as a result, SentinelOne's Annualized Recurring Revenue ("ARR") was overstated; and (iii) consequently, SentinelOne's guidance was overstated. About Johnson Fistel, PLLP | Top Law Firm, Securities Fraud, Investors Rights: Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. We also extend our services to foreign investors who have purchased on US exchanges. Stay updated with news on stock drops and learn how Johnson Fistel, PLLP can help you recover your losses. For more information about the firm and its attorneys, please visit Achievements: In 2024, Johnson Fistel was honored to be ranked in the Top 10 Plaintiff Law Firms by the ISS Securities Class Action Services. This recognition underscores our effectiveness in advocating for investors, having recovered approximately $90,725,000 for aggrieved clients in cases where we served as lead or co-lead counsel. This notable accomplishment marks the eighth occasion our firm has been recognized as a top plaintiffs' securities law firm in the United States, as determined by the total dollar value of final recoveries. Attorney advertising. Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.
Business Wire
an hour ago
- Business Wire
FiberStar Selects Incognito Software Systems to Optimize Fiber Network and Enhance Wi-Fi Service Quality
VANCOUVER, British Columbia--(BUSINESS WIRE)--PT. Mega Akses Persada (FiberStar), a leading fiber operator in Indonesia, has announced its partnership with Incognito Software Systems, a leading global provider of broadband service orchestration, device management, and network intelligence OSS solutions, to deploy its Digital Experience (DX) Solution to streamline multi-vendor device management and optimize Wi-Fi service quality. With Incognito's solution, FiberStar can take advantage of market-leading TR-069 and Wi-Fi management capabilities to enhance key customer journeys, such as service activation, performance management, and issue resolution. The swift deployment of Incognito's DX Solution provides network-wide visibility and control over FiberStar's fiber network devices, helping cut costs, reduce demands on operational teams, and improve the quality of experience of all subscribers. Share With a focus on designing, building, and operating high-quality, open-access fiber infrastructure that enables enterprise customers and communication service providers to offer triple-play services across 200 cities in Indonesia, FiberStar required a robust device management solution capable of supporting end-to-end provisioning and monitoring of Optical Network Terminals (ONTs) across its network while maintaining visibility of in-home Wi-Fi performance. Thanks to the flexible architecture and standards-based approach of Incognito's solution, the deployment was completed swiftly in just a matter of weeks, allowing FiberStar to quickly enhance its service delivery. Incognito's DX Solution equips FiberStar with real-time visibility into in-home Wi-Fi performance, enabling remote diagnostics, proactive troubleshooting, and seamless configuration updates across multi-vendor devices. This ensures optimized connectivity, reduced service disruptions, and faster resolution of Wi-Fi issues, leading to improved customer satisfaction and trust. Key features of the solution include: Standards-based TR-069 device management and provisioning that is network access agnostic and vendor-neutral; Centrally managed device configurations, including firmware updates, reboots, and parameter changes, to streamline operational processes; Advanced service quality management to validate connection quality, perform automated network-wide monitoring, and conduct individual device diagnostics; Real-time alerts and reporting to provide deeper insights into network performance and long-term trends. 'At FiberStar, we are committed to delivering top-tier fiber services to customers across Indonesia,' says Sugiharto Darmakusuma, President Director at FiberStar. 'By selecting Incognito's proven carrier-grade solution, we can improve operational efficiencies while continuing to meet the growing demands of the Indonesian IT market and exceed customer expectations.' To support this project, Incognito worked with PT Multipolar Technology Tbk to ensure a seamless deployment of the DX Solution for FiberStar. Multipolar Technology played a key role in understanding the networking requirements, facilitating stakeholder collaboration, and ensuring a smooth implementation that enhances FiberStar's service offerings. 'Through our collaboration with Incognito, Multipolar Technology has provided FiberStar with a best-in-class and telco standard device management solution (FTTH multi-vendor ONT management) empowering them to deliver exceptional connectivity experiences,' said Yugi Edison, Director Account Management Telco and Public Sector at Multipolar Technology. 'We are excited to continue this collaboration with FiberStar to foster innovation throughout the region.' 'Incognito is proud to be a key enabler of FiberStar's network growth goals,' said Gary Knee, CEO of Incognito. 'The swift deployment of our DX Solution provides network-wide visibility and control over FiberStar's fiber network devices, helping cut costs, reduce demands on operational teams, and improving the quality of experience of all subscribers.' About Incognito Software Systems Inc. Incognito Software Systems Inc. provides service orchestration software and services that help digital service providers manage the next-generation broadband experience. Founded 30 years ago, Incognito has over 200 customers worldwide, including America Movil, Cox, Digicel, Globe, and Orange, leveraging its solutions to fast-track the introduction of innovative broadband services over fiber and 5G fixed wireless access technologies, while delivering a great customer experience. Incognito Software Systems is a Lumine Group company (TSXV: LMN). Visit or follow us on LinkedIn and X (Twitter).
Yahoo
2 hours ago
- Yahoo
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif., June 11, 2025--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on June 10, 2025, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 115,620 shares of common stock and 57,740 restricted stock units ("RSUs") to 10 new employees under Mirum's 2020 Inducement Plan. The Compensation Committee of Mirum's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $48.98 per share, Mirum's closing trading price on June 10, 2025, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees' continued service relationship with Mirum through the applicable vesting dates. The RSUs will vest over three years, with 33% of the underlying shares vesting on each anniversary of the applicable vesting commencement date, subject to the new employees' continued service relationship with Mirum through the applicable vesting dates. The awards are subject to the terms and conditions of Mirum's 2020 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant. About Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat), CHOLBAM® (cholic acid) capsules, and CTEXLI™ (chenodiol) tablets. LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally. It is also approved in the U.S. in cholestatic pruritus in PFIC patients 12 months of age and older; in Europe, it is approved for patients with PFIC three months of age and older. Mirum is also initiating the Phase 3 EXPAND study, a label expansion opportunity for LIVMARLI in additional settings of cholestatic pruritus. CHOLBAM is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms of liver disease. CTEXLI is FDA-approved for the treatment of cerebrotendinous xanthomatosis (CTX) in adults. Mirum's late-stage pipeline includes two investigational treatments for several rare diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2 VISTAS study for primary sclerosing cholangitis (PSC) and Phase 2b VANTAGE study for primary biliary cholangitis (PBC). Volixibat has been granted Breakthrough Therapy Designation for the treatment of cholestatic pruritus in patients with PBC. Mirum is also planning for a Phase 2 study evaluating MRM-3379, a PDE4D inhibitor for the treatment of Fragile X syndrome, a rare genetic neurocognitive disorder. To learn more about Mirum, visit and follow Mirum on Facebook, LinkedIn, Instagram and X. View source version on Contacts Investor Contact: Andrew McKibbenir@ Media Contact: Erin Murphymedia@ Sign in to access your portfolio
